Why in news?

Recent episodes involving Ebola, hantavirus, and Nipah virus show that dangerous zoonotic infections are no longer rare, isolated events.

They are appearing with increasing regularity at the interface of humans, animals, forests, farms, hospitals, and global travel — exposing weaknesses in surveillance, public trust, vaccine access, and international preparedness.

What’s in Today’s Article?

• Understanding the Three Viruses
• The Vaccine Gap
• Building Preparedness: From Research to Vaccine
• Why Vaccine Development Lags for These Viruses?
• The Way Forward
• Conclusion

Understanding the Three Viruses

• Ebola Virus Disease
  • Causes severe illness and death, with an average case-fatality rate of around 50%.
  • Recent cases in central Africa illustrate how conflict, displacement, unsafe burials, distrust of health workers, and weak surveillance make outbreak control extremely difficult.
  • Transmits human-to-human through infected body fluids.
• Hantavirus
  • Named after the Hantaan River region in South Korea; mainly rodent-borne.
  • Causes kidney disease or hantavirus pulmonary syndrome — a severe lung illness that can rapidly progress to respiratory failure and shock.
  • A cluster linked to the MV Hondius cruise ship revived public attention, showing how a locally confined virus can acquire international significance through travel, enclosed spaces, and multi-country contact tracing.
  • Unlike most hantaviruses, the Andes hantavirus strain shows limited person-to-person spread.
• Nipah Virus
  • Carried mainly by fruit bats; causes respiratory illness and encephalitis.
  • Case-fatality rates estimated at 40–75%.
  • Recurring concerns in India and Bangladesh confirm it remains a persistent regional threat.
  • Spreads through close household or healthcare contact.

The Vaccine Gap

• A licensed vaccine exists for only one major Ebola virus species.
• No licensed human vaccines currently exist for Bundibugyo Ebola, Nipah virus, or hantavirus infections.
• No reliable curative treatment exists once outbreaks begin, making early detection, isolation, and infection control critical.

Building Preparedness: From Research to Vaccine

• Step 1 — Basic research: Understanding pathogen biology — how it enters cells, causes disease, and which proteins trigger immunity — largely happens in publicly funded universities and national laboratories.
• Step 2 — Industrial translation: Converting research into usable vaccines requires industrial-scale capacity: process development, formulation, quality control, regulatory documentation, clinical trials, manufacturing, and cold-chain planning.
• Role of new technology: AI tools can now help identify vaccine targets, predict immune responses, compare candidates, and improve manufacturing — though conventional biological validation, safety testing, and regulatory review remain essential.
• Platform technologies like mRNA vaccines, viral vector vaccines, and recombinant protein systems can accelerate design once a pathogen's genetic sequence or protective antigen is identified.

Why Vaccine Development Lags for These Viruses?

• COVID-19 proved vaccine design, testing, and scale-up can move far faster than previously believed — but these platforms aren't freely available to all researchers, as many depend on patents, proprietary know-how, and specialised manufacturing controls.
• Testing challenges: Outbreaks of Ebola, hantavirus, and Nipah are often unpredictable, making conventional large clinical trials difficult. This may require emergency trial designs, ring-vaccination studies, adaptive protocols, and regional trial networks.
• Economic disincentive: International vaccine companies may find limited financial attraction in developing vaccines for diseases with small, uncertain outbreaks in poorer regions — despite enormous public-health value.

The Way Forward

• Academia-industry partnerships: Academic institutions provide immunology expertise, animal models, and early vaccine concepts; industry provides scale-up, formulation, quality assurance, and distribution.
• Shared-risk financing model: Since standard profit models fail to reward epidemic vaccine development, the solution may lie in public funding, advance purchase commitments, technology transfer, regional manufacturing capacity, and fair global stockpiles.
• Addressing vaccine hesitancy: Fear, misinformation, and distrust during outbreaks can prevent people from accepting vaccines or cooperating with contact tracing and isolation measures. Trust must be built before emergencies arise, through honest communication, local leadership, and transparent risk communication.

Conclusion

Ebola, hantavirus, and Nipah illustrate that pathogens do not respect borders — a disease originating in a forest village or aboard a ship can become an international concern within days.

Genuine preparedness demands overcoming a scientific challenge and building public-private, academic-industrial, and international systems that can develop vaccines in time, distribute them fairly, and earn the community trust needed to use them.